RegenPRP™

The standardised leucocyte-reduced
platelet concentrate prepared with
RegenLab® technology that provides
an autologous reservoir of growth factors.

What is RegenPRP™ ?

1.1 – Platelets

In addition to their role in haemostasis, platelets are key factors in tissue repair mechanisms.1 They provide essential growth factors, such as FGF, PDGF, TGF-β, EGF, VEGF, IGF, which are involved in stem cell migration, differentiation, and proliferation. Platelet growth factors also stimulate fibroblasts and endothelial cells to induce the deposition of new extracellular matrix and neo-vascularisation, respectively.

1.2 – Plasma

Plasma contains many factors essential for cell survival including nutrients, vitamins, hormones, electrolytes, growth factors (such as IGF and HGF), and proteins. Among the plasma proteins, the molecules involved in the coagulation process allow the formation of the fibrin polymer that serves as a scaffold for cell migration and new tissue generation.2

1.3 – Platelet Rich Plasma (PRP)

  • Proven efficacy in tissue healing, with key roles in cell migration, proliferation, and differentiation

  •  Mechanism of action comprises anti-inflammatory activity and activation of cell-signalling cascades

  • Key role in the synthesis of new extracellular matrix for tissue regeneration

Technology advantages

————–

  • User-independent standardised preparation

  • Minimum volume of blood required

  • Safe closed-circuit system

  • Mechanical separation of PRP using a chemically inert separator gel with a single centrifugation at a relative centrifugal force of 1500 x g

  • Pharmaceutical grade solution of sodium citrate allowing a reversible anticoagulation

  • Addition of Autologous Thrombin Serum (ATS prepared with RegenATSdevice), either alone or combined with a calcium solution, allows to obtain RegenPRP™ in different jellified forms

  • Minimal learning curve and ease of use

  • Operationally and clinically efficient process

  • Facilitates and streamlines routine practice

Scientific advantages

————–

  • Demonstrated safety and efficacy

  • Evidence-based outcomes for numerous therapeutic indications

  • Large number of clinical studies, with over 200 publications

Biological advantages

————–

  • RegenPRPis standardised, leucocyte-reduced and easily reproducible

  • RegenLab® specific separator gel technology guarantees minimal variability

  • Platelet recovery > 80%

  • High platelet quality. Viable & functional platelets

  • Full plasma recovery. No loss of plasma growth factors and fibrinogen

  • Leucocyte-reduced PRP. Depletion of ~ 96% of pro-inflammatory granulocytes, leaving mainly lymphocytes and monocytes

  • Virtually no red blood cells. Depletion of ~ 99.7% of erythrocytes

Technology advantages

The technology ensures consistent PRP preparation with minimal blood, using a safe, closed system and inert separator gel after a quick 5-minute centrifugation at 1500g. It includes pharmaceutical-grade sodium citrate for reversible anticoagulation, is easy to use with minimal training, and streamlines routine clinical practice efficiently.

Biological advantages

RegenLab®'s separator gel ensures reproducible results with over 80% platelet recovery, high platelet quality, full plasma recovery, and minimal red blood cells. It produces leucocyte-reduced PRP, preserving essential growth factors and fibrinogen.

Scientific advantages

The technology's scientific advantages include demonstrated safety and efficacy, with evidence-based outcomes for various therapeutic indications. Supported by over 200 clinical studies, it has a robust foundation of research confirming its effectiveness.

Since 2003, Regen Lab SA has been committed to the development of a unique expertise for the design and manufa​cturing of high-quality medical devices.

Copyright © 2024 All rights reserved.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ est un traitement médical qui utilise le plasma riche en plaquettes provenant du sang du patient pour améliorer et la régénération tissulaire.

RegenPRP™ - HA

Cellular Matrix® est un traitement innovant combinant le plasma riche en plaquettes (PRP) et l'acide hyaluronique pour améliorer la régénération tissulaire et la guérison.

RegenPRP™ - ATS

RegenPRP™ combiné avec ATS (Autologous Thrombin Serum) est une approche avancée pour la régénération tissulaire qui utilise le plasma riche en plaquettes (PRP) enrichi en thrombine autologue pour maximiser les effets de guérison.

RegenExtracell®

RegenExtracell est un traitement innovant axé sur la régénération tissulaire qui utilise une matrice extracellulaire enrichie en plasma riche en plaquettes (PRP).

Hyaluronic Acid

L'acide hyaluronique est une substance naturellement présente dans le corps humain, particulièrement dans la peau, les articulations et les yeux.

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.

Safety & Privacy policies

WEBSITE PRIVACY NOTICE

We recommend you to acquaint yourself with the full content of our Privacy Policy.